Author recommends March 2026 calls on Eli Lilly, expecting retatrutide FDA approval as a catalyst.
LLY — LONG The author argues Eli Lilly will appreciate because its investigational GLP-1 retatrutide is described as better than semaglutide and tirzepatide and could receive FDA approval around March 2026. The recommendation is to buy March 2026 calls, a bullish position whose returns would track LLY.
Yall buy calls for LLY March 2026, Retatrutide new glp fda approval somewhere around there. Better glp then semaglutide and tirzepatide
This Reddit post, published January 05, 2026, features u/Mihermano2002 discussing LLY. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Mihermano2002 · Tickers: LLY